Covered recipient · General Payments record
LEE M WEINBERG
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$1,072.58
- Reported across 56 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $241.28 | 15 |
| Education | $46.64 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $134.94 | 10 |
| Takeda Pharmaceuticals U.S.A., Inc. | $49.35 | 2 |
| Celltrion USA Inc. | $46.64 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $40.67 | 2 |
| Celgene Corporation | $16.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.52 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319297 | CMS |
| ABBVIE INC. | $20.97 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319299 | CMS |
| ABBVIE INC. | $4.34 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319301 | CMS |
| ABBVIE INC. | $5.52 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319303 | CMS |
| ABBVIE INC. | $27.51 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319305 | CMS |
| ABBVIE INC. | $14.15 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319307 | CMS |
| ABBVIE INC. | $1.85 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319309 | CMS |
| ABBVIE INC. | $2.72 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319311 | CMS |
| ABBVIE INC. | $27.05 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319313 | CMS |
| ABBVIE INC. | $5.31 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106319315 | CMS |
| Celgene Corporation | $16.32 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101089317 | CMS |
| Celltrion USA Inc. | $23.34 | 08/14/2024 | Education | Undisputed | 01/23/2026 | 1075859717 | CMS |
| Celltrion USA Inc. | $23.30 | 09/17/2024 | Education | Undisputed | 01/23/2026 | 1075859719 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $20.44 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153771646 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $20.23 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153767013 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.79 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137695836 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.56 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137695838 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.